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Marinemolluscs from the familyMuricidae are under development as a potential medicinal food for the prevention of colon cancer
and treatment of gynaecological cancers. Here we report the outcome of the first in vivo toxicity assessment on an anticancer extract
from a muricid mollusc containing brominated indole derivatives. Mice received the concentrated lipophilic extract by daily oral
gavage over a two-week period.Mortality or clinical toxicity symptoms resulting from the extract were not detected during the trial,
and there was no difference in the body weight of treated and control mice at the end of the trial. Histological analysis revealed some
evidence for mild, idiosyncratic effects on the gastrointestinal tract and liver, including necrosis, fatty change, and inflammation
in a small proportion (<40%) of mice. This is likely to result from first-pass hepatic metabolism of tyrindoxyl sulphate combined
with second-pass metabolism of indoles. Overall however, oral administration of muricid extract containing brominated indoles
does not result in severe clinical toxicity.
1. Introduction
Predatory molluscs (whelks) in the family Muricidae are well
known for the production of bioactive brominated indoles,
which are precursors to the ancient dye Tyrian purple [1–
5]. Recently, the purified brominated indoles fromMuricidae
have been demonstrated to induce apoptosis and specifi-
cally inhibit female reproductive cancers, with a little effect
on healthy primary granulosa cells in vitro [2]. Lipophilic
extracts derived from these molluscs have also been shown
to stimulate the acute apoptotic response to DNA damage in
the distal rodent colon [6]. Stimulation of the acute apoptotic
response to genotoxic carcinogens (AARGC) has recently
become a promising new target for the chemoprevention
of colorectal cancer (CRC) as it represents a homeostatic
response to DNA-adduct formation [7]. Natural products
such as cannabidiol [8], prebiotics, resistant starch [9, 10],
wheat bran [7, 11, 12], and selenium [13] have all been shown
to enhance the AARGC. Dose-dependent enhancement of
the acute apoptotic response to a genotoxic carcinogen
(AARGC) was also achieved with a crude extract fromMuri-
cidae molluscs containing brominated indoles, after daily
oral administration of the muricid extract over a one-month
period [6]. As muricids comprise a traditional component of
African [14], European [15], Mediterranean [16], and Asian
[17] diets, there is excellent potential for the development of
these marine molluscs as a novel medicinal food, particularly
for CRC prevention.
Colorectal cancer (CRC) accounts for 65% of new can-
cer cases in affluent countries and ∼9.4% of cancer cases
worldwide, with an annual mortality rate of ∼50% [18]. Over
80% of these cases [19] arise through cumulative exposure to
alkylating agents [20, 21] and heterocyclic amines [22]. These
exogenous carcinogens promote cell proliferation through
the formation of DNA adducts and somaticmutations, which
ultimately result in cell cycle and apoptotic dysregulation
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[23]. In western countries, CRC incidence and return are∼10-
fold greater than in countries such as India, Asia, and Africa
[18], where natural chemopreventatives comprise a regular
part of the diet. The chemopreventative capacity and speci-
ficity of natural products such as rhein (an anthraquinone
isolated from Cassia species) [24], curcumin (turmeric pig-
ment), indole-3-carbinol (cruciferous vegetables), tricin (rice
beans), diallyl disulphide (garlic), soybean saponin and car-
damom are substantiated by their ability to modulate signal
transduction pathways and induce CRC cell cycle arrest and
apoptosis [25].
The historical and ongoing consumption of muricid meat
implies an absence of symptomatic toxicity. Nevertheless,
the potential for toxicity associated with ingestion of a con-
centrated bioactive extract requires consideration. Drug-
induced injury is common in the gastrointestinal tract and
liver [26], with the latter representing a major cause of drug
candidate withdrawal [27]. Although in vivo evidence implies
tyrindoleninone and/or 6-bromoisatin selectively induces
apoptosis in DNA-damaged cells [6], in vitro assessment
suggests their mode of action and selectively depends on
the cell type and the concentration of bioactive brominated
compounds [1, 2, 28].
In addition to direct toxicity, drugs may indirectly induce
toxicity through the accumulation of toxicmetabolites. Effec-
tive detoxification of tyrindoleninone and 6-bromoisatin is
expected, as indole and isatin metabolism is an endoge-
nous mechanism for the detoxification of metabolites gen-
erated during tryptophan metabolism by intestinal bacteria
[29]. Furthermore, the cytochrome P450 isoforms CYP2A6,
CYP2E1 [30], and glutathione-S-transferase (GST) [31] have
been implemented in the hepatic debromination of xenobi-
otics. Although conjugates (i.e., indoxyl sulphate and glu-
curonide) and minor oxidative metabolites (i.e., indoxyl, 6-
hydroxyindole) are generally excreted in the urine [32, 33],
enzyme substrate saturation may result in the accumulation
of metabolites. One example is indoxyl sulphate, which is a
uraemic toxin [34] that stimulates production of reactive oxy-
gen species (ROS) [35]. Thus, although endogenous mech-
anisms are in place for the metabolism of Tyrian purple
precursors, the additional metabolic load from concentrated
extract administration may result in hepatotoxicity.
To facilitate the progression of bioactive extracts from
muricid molluscs into clinical trials as a chemopreventative,
this investigation aims to determine if daily administration of
the extract induces in vivo gastrointestinal and hepatotoxicity.
As gastric exposure results in the oxidation of tyrindoleni-
none to 6-bromoisatin [6], it is uncertain what proportion of
the extract escaped gastric oxidation in our previous in vivo
trial [36]. Consequently, an extract preparation containing
mostly 6-bromoisatin was administered by oral gavage in
this study.The extract dosages employed correlate with those
known to enhance the AARGC [6].
2. Experimental Section
2.1. Muricid Extraction and Chemical Analysis. The Muri-
cidae Dicathais orbita (Neogastropoda, Mollusca) and egg
masses were collected from the rocky intertidal of the
Fleurieu Peninsula, and from a population held in the
Flinders University marine aquarium, South Australia. The
muricid extract was prepared according to Westley et al. [6]
and exposed to air prior to storage at −20∘C. The secondary
metabolite composition of each extract batchwas determined
by high-performance liquid chromatography (HPLC, Waters
Alliance) coupled to a mass spectrometer (MS, Micromass
Quatro micro) according to Westley and Benkendorff [37].
Compounds were identified according to retention times
and characteristic major and fragment ion clusters [37]. The
relative concentration of each compoundwas calculated from
the integrated peak area in diode-array using MassLynx 4.0
software and expressed as the mean percentage (±S.D.) of the
total precursor composition across both extract batches.
2.2. InVivo RodentModel Experimental Procedure and Sample
Collection. All experimental procedures were approved by
the FlindersUniversity and SouthernAdelaideHealth Service
Animal Welfare Committee (Project no. 632/07). After a
7d acclimation period, 8-week old female C56BL/6J mice
(𝑁 = 28) were randomly assigned to one of four groups:
(1) 0.0mg/g control (200𝜇L of sunflower oil, 𝑛 = 4), (2)
0.125mg/g muricid extract in sunflower oil (𝑛 = 8), (3)
0.5mg/g extract in sunflower oil (𝑛 = 8), and (4) 1.0mg/g
extract in sunflower oil (𝑛 = 8). Mice were housed (4/cage)
and maintained in a temperature- and humidity-controlled
animal facility with a 12 h light-dark cycle (Flinders Medical
Centre, South Australia). Muricid extract was administered
daily by oral gavage, and animals were fed ad libitum on
rodent chow and autoclaved water. Animals were weighed
a day prior to the first extract dose and at regular intervals
throughout the 14-day experimental period. Mice were also
observed for toxicity symptoms as defined in the Common
ToxicityCriteria developed by theCancerTherapy Evaluation
Program [38]. These included loss of appetite, vomiting,
constipation, diarrhoea, dysphagia (inability to swallow),
hematemesis (vomiting blood) and hematochezia (bloody
stools). Excrement samples (combined stools and urine) were
collected fromanimals administered oil alone (control, 𝑛 = 4)
and those receiving 1.0mg/g muricid extract (𝑛 = 8) on
days 7 and 14. Excrement samples were pooled according
to treatment dose and analysed by LCMS for the presence
of unmetabolized Tyrian purple precursors and brominated
compounds, as described above.
Mice were killed on day 14 by CO
2
-induced narcosis
followed by cervical dislocation. Visceral organs (colon, small
intestine, liver, spleen, and kidneys) were excised immedi-
ately postmortem and weighed. Organ weights are expressed
as amean percent of total bodyweight. Colon, small intestine,
and liver were then fixed in 10% neutral buffered formalin
for histological assessment. Three animals were euthanized
early in accordance with Flinders University Animal Welfare
approval no. 632/07 due to overgrown teeth and handling
stress associated with the oral gavage procedure. Conse-
quently, histology was only carried out on 7 animals admin-
istered 0.5mg/g and 6 administered 1.0mg/gmuricid extract,
in addition to all 8 administered 0.125mg/mL and the 4
controls.
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2.3. Gastrointestinal and Hepatotoxicity Assessment. Vari-
ables assessed by histology were indicative of antimitotic or
cytotoxic drug-induced toxicity [26, 38]. Triplicate sections
were examined for each organ (small intestine, colon, liver)
from each mouse. Small intestine and colon sections were
examined with a light microscope (Zeiss, Axio Imager, A1)
and digital images acquired (Zeiss, AxioCam, ICc1). Mea-
surements (0.01𝜇m) were obtained using Axio Vision 8.8
software (Zeiss, 2006-09). Hepatocyte sections were exam-
ined under a BH-2 light microscope (Olympus, Japan) and
measurements (0.01𝜇m) were obtained in Adobe Photoshop
version 5.5 (Adobe Systems Incorporated, 1999) in accor-
dance with a stage micrometer.
Small intestine toxicity indicators included inflamma-
tion, ulceration, haemorrhage, villous hyper/hypoplasia and
mucosal atrophy. Duodenum and ileum segments (0.5mm)
were paraffin-embedded, sectioned at 5 𝜇m and stained with
haematoxylin and eosin. Triplicate sections from eachmouse
were examined for the presence of inflammation, ulceration,
haemorrhage, and atrophy. Fourteen randomly chosen villi
in each section were assessed for hyper/hypoplasia, which
was quantified by determining villous height (cells/villi), cell
density (cells/𝜇m), and the height of crypts of Lieberkühn
(𝜇m).
Colon toxicity indicators included mucosal inflamma-
tion, crypt abscesses, ulceration, crypt hyper/hypoplasia and
dysplasia. Proximal and distal colon segments (0.5mm) were
paraffin embedded, sectioned at 5 𝜇m, and stained with
haematoxylin. Whole triplicate sections from each mouse
were examined for the presence of inflammation, abscesses
and ulcers. Hyper/hypoplasia was quantified from 14 ran-
domly chosen complete crypts by determining the crypt
height (cells/crypt) and cell density (cells/𝜇m).
Hepatotoxicity indictors included Mallory bodies, por-
phyrin, porphyrin, haemosiderin, lipofuscin, peliosis (blood-
filled cysts)/haemorrhage, hepatocellular hyperplasia and
hypertrophy, necrosis, steatosis (fatty change), and inflam-
mation. Liver sections were paraffin embedded, sectioned
at 5 𝜇m, and stained with haematoxylin and eosin for mor-
phological examination. Steatosis was confirmed in tissue
embedded in O.C.T. (Tissue-Tek) and cryostat sectioned at
10 𝜇m and stained with Oil Red O for the demonstration
of neutral lipids [39]. Triplicate liver sections from each
mouse were examined for the presence of Mallory bodies,
porphyrin pigment, steatosis, peliosis, and necrosis. When
present, necrosis was additionally classified based on location
(zone 1: periportal; zone 2: midzonal; zone 3: centrilobular)
and severity (single cell, focal, submassive, or massive).
Hyperplasia was determined by quantifying hepatocyte den-
sity (nuclei/mm2) within 10 random fields (1mm2) for each
mouse. Inflammatory infiltrate frequency, severity (grade 1,
>5 ≤10; grade 2, >10 ≤20; grade 3, >20 ≤30; grade 4, >30
leucocytes) and location (zone 1; zone 2; zone 3), was deter-
mined within 20 random fields of view. Hypo/hypertrophy
was determined by measuring the diameter of 10 hepatocytes
within five random fields of view for each mouse.
2.4. Statistical Analysis. Statistical analyses were conducted
in PASW Statistics 18TM (SPSS Inc., Chicago, IL., USA, 2009)
for Microsoft Windows. Analysis of variance (ANOVA, 𝑃 <
0.05) and post Hoc (Tukey HSD) pairwise analyses were
performed to determine significant differences between con-
trol animals (0.0mg/g, 𝑛 = 4) and those administered
0.125mg/g (𝑛 = 8), 0.5mg/g (𝑛 = 7), or 1.0mg/g (𝑛 =
6) of muricid extract in oil. Variables subjected to ANOVA
(transformations given in brackets) included colon, liver, and
spleen percent weight, duodenum villous height and cell
density, ileum villous height, proximal colon crypt height, cell
density, distal colon crypt height and cell density (log 10),
and hepatocyte density, diameter (log 10) and zone 1 liver
inflammation distribution. In cases where transformation
failed to meet the assumptions of normality and equal
variances (Levene Statistic) for ANOVA, a nonparametric
Kruskal-Wallis (𝑃 < 0.05) followed by Mann-Whitney U
pair-wise analyses between the control and each dose were
employed (Bonferroni correction 𝛼 = 0.017). Nonparametric
analyses were performed on the following variables: total
weight change, small intestine and kidney percent weight,
duodenum and ileum crypt of Lieberkühn depth, ileum cell
density, liver sinusoid diameter, and inflammation severity
(grade 1–4) and distribution (zone 2 and 3).
3. Results and Discussion
3.1. Muricid Extract and Excrement Chemical Composition.
Gastrointestinal toxicity and hepatotoxicity was assessed after
oral administration of an extract preparation that had been
exposed to air, as gastric exposure [6] and boiling the snails
for consumption (Benkendorff unpublished data), results
in tyrindoleninone oxidation to 6-bromoisatin. Analysis
of the extract by LCMS confirmed the dominance of 6-
bromoisatin (𝑡
𝑅
= 6.4min; ES– m/z 224, 226), with a mean
relative concentration of 67.40 ± 12.51%, in our preparation,
which is similar to that observed postgastric exposure [6].
Four other brominated indole precursors of Tyrian pur-
ple were also detected, which is consistent with previous
reports on the composition of muricid extracts [1, 2, 4, 37].
Tyrindolinone (𝑡
𝑅
= 9.5min; ES− m/z 302, 304; 11.32 ±
7.22%), tyriverdin (𝑡
𝑅
= 12.0min; ES− m/z 511, 513, 515;
7.36 ± 3.49%), tyrindoleninone (𝑡
𝑅
= 11.2min; ES+ m/z
256, 258; 7.04 ± 0.18%), and tyrindoxyl sulphate (𝑡
𝑅
=
5.5min; ES− m/z 336, 338; 6.88 ± 1.61%) were present
in descending order of relative concentration. Analysis of
extracts from excrement samples collected on day 7 or 14
from mice receiving oil alone (control), or 1.0mg/g muricid
extract, failed to reveal the presence of any HPLC peaks with
brominated ions corresponding to Tyrian purple precursors
in themass spectrometer.This suggests complete metabolism
of the bioactive indoles in vivo.
3.2. In Vivo Rodent Model General Observations and Weight.
This investigation constitutes the first in vivo toxicological
assessment of bioactive extracts from muricid molluscs, as a
novel andpromisingmedicinal food for the chemoprevention
of CRC. No visible signs of ill effects were observed for any
of the mice, and the general condition of mice that received a
daily dose of 0.125mg/g, 0.5mg/g, or 1.0mg/gmuricid extract
was similar to controlmice.Therewas nomortality or toxicity
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Table 1: Mean (±S.D.) organ weight as a percent of total body weight in control mice (0.0mg/g, 𝑁 = 4) and mice administered 0.125mg/g
(𝑁 = 8), 0.5mg/g (𝑁 = 7) and 1.0mg/g (𝑁 = 6) of muricid extract (ME). Significant differences (𝑃 < 0.05) between control and ME-treated
mice are indicated by ∗.
ME dose (mg/g) Percent of body weight (%)Colon Small intestine Liver Kidney Spleen
0.000 0.68 ± 0.22 3.47 ± 1.33 5.11 ± 0.66 1.43 ± 0.08 0.36 ± 0.03
0.125 0.78 ± 0.07 4.17 ± 0.29 4.29 ± 0.16∗ 1.40 ± 0.08 0.41 ± 0.04
0.500 0.71 ± 0.13 4.53 ± 0.74 4.76 ± 0.33 1.43 ± 0.09 0.39 ± 0.05
1.000 0.92 ± 0.09∗ 4.65 ± 0.19∗ 5.26 ± 0.26 1.65 ± 0.04∗ 0.42 ± 0.04
symptoms such as loss of appetite, vomiting, constipation,
diarrhoea, dysphagia, hematemesis, or hematochezia [38]
after daily administration of the muricid extract over a 14 d
period. Animals from all groups developed an oily sheen to
their coat.
Mean body weight decreased for all groups after day 2,
before attaining a plateau (Figure 1). After day 9, the weight
of control animals steadily increased, while after day 12 the
weight of all treatment animals decreased to below their start
weight (Figure 1). Nevertheless, no significant differences in
mean total weight change were detected (𝑃 = 0.377). Treated
mice showed some small but statistically significant changes
in organ weight. Small intestine weight displayed a dose-
dependent increase (Table 1), with a significant increase of
0.09 g (0.48% of body weight) detected between animals
administered 0.125mg/g and 1.0mg/g extract (𝑃 = 0.008).
Mean colon weight was similar between control animals and
those administered 0.125mg/g and 0.5mg/g extract (Table 1).
A significant increase of 0.03 g in colonweight (0.24%of body
weight) was apparent in animals receiving 1.0mg/g extract in
comparison to animals in control (𝑃 = 0.034) and 0.5mg/g
extract groups (𝑃 = 0.034).The liver ofmice administered the
low extract dose of 0.125mg/g were on average 0.25 g smaller
than control mice (0.82% of body weight, 𝑃 = 0.004) and
0.19 g smaller than mice administered the top extract dose of
1mg/g (0.97%of bodyweight,𝑃 < 0.001) (Table 1).Mean kid-
ney weight was significantly greater in animals administered
1.0mg/g extract than control animals (𝑃 = 0.001) and those
receiving 0.125mg/g (𝑃 < 0.001) and 0.5mg/g (𝑃 < 0.001)
muricid extract, but only by 0.02 (0.22%), 0.04 (0.25%), and
0.03 g (0.22%) in kidneyweight (% bodyweight), respectively,
(Table 1). No significant differences in mean spleen weight
were observed between control animals and all treatment
groups (Table 1, 𝑃 = 0.194).
3.3. Gastrointestinal Effects: Small Intestine. Drug-induced
gastrointestinal toxicity depends on the mode of drug
absorption and the capacity and rate of first-pass intestinal
metabolism. The small intestine is the predominant site of
drug absorption [40] and contains various cytochrome P450
monooxygenases (CYP) (phase I) and conjugation enzymes
(phase II) [41]. First-pass intestinal metabolism only occurs
during transcellular absorption of lipophilic compounds,
while small or hydrophilic molecules undergo paracellu-
lar absorption and first-pass hepatic metabolism [41]. As
tyrindoleninone and 6-bromoisatin are lipophilic, transcellu-























Figure 1: Comparison ofmean (±S.D.) progressive bodyweight over
the trial duration for controlmice (X,𝑁 = 4) andmice administered
0.125mg/g (◼,𝑁 = 8), 0.5mg/g (󳵳,𝑁 = 7), and 1.0mg/g (×,𝑁 = 6)
muricid extract in sunflower oil daily.
Some evidence for possible gastrointestinal effects asso-
ciated with the muricid extract was detected in the small
intestine. Histologically, gastrointestinal toxicity in the small
intestine was characterised by villous hyperplasia in the
duodenum. No haemorrhage or ulcers were observed in
duodenum and ileum sections from control mice or any of
the mice administered muricid extract. Abscesses associated
with localised crypt atrophy and mild to chronic inflam-
mation of the lamina propria were only observed in one
of the seven mice administered 0.5mg/g of the muricid
extract (Figure 2(a)). The duodenum of control animals and
those administered 0.125mg/g and 1.0mg/g muricid extract
failed to display any signs of inflammation or atrophy. The
mean height of villi in the duodenum of animals receiving
0.125mg/g (𝑃 = 0.015), 0.5mg/g (𝑃 = 0.010), and 1.0mg/g
(𝑃 = 0.018) extract was significantly greater than that of
control animals (Table 2). Villous epithelial cell density was
significantly greater in mice receiving 0.5mg/g (𝑃 < 0.001),
and 1.0mg/g (𝑃 = 0.023) extract in comparison to control
mice (Table 2). Villus cell density in the duodenum of mice
treated with 0.125mg/g extract was not significantly different
to the controls (𝑃 > 0.05). No clear trend between duode-
num crypt depth and extract dose was apparent (Table 2).
However, mice administered 0.125mg/g (𝑃 < 0.001) and
1.0mg/g (𝑃 < 0.001) extract had significantly shortened
crypts (∼11 𝜇m) compared to control mice.
No signs of inflammation or atrophywere observed in the
ileum of control animals and those administered the highest
dose of muricid extract (1mg/mL). However, chronic inflam-
mation together with crypt and villous atrophy occurred
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(a) (b)
Figure 2: Transverse sections of small intestinal abscesses stained with haematoxylin. (a) Duodenal abscess with mild inflammation and
localised crypt atrophy in a mouse administered 0.5mg/g muricid extract, and (b) an abscess in the ileum of a mouse receiving 0.125mg/g
muricid extract characterised by chronic inflammation and extensive crypt and villous atrophy. Abbreviations: A, artery; C, crypt of
Lieberkühn; IF, inflammatory infiltrate; LP, lamina propria; LU, lumen; MS, muscularis; V, vein; VIL, villi.
Table 2:Mean (±S.D.)morphometric values for small intestine toxicity indicators in controlmice (0.000mg/g,𝑁= 4) andmice administered
0.125mg/g (𝑁 = 8), 0.5mg/g (𝑁 = 7), and 1.0mg/g (𝑁 = 6) muricid extract (ME). Significant differences between controls and extract doses
are indicated by ∗ (Tukey, 𝑃 < 0.05; Mann-Whitney, 𝑃 < 0.017).








0.000 74.25 ± 15.43 0.18 ± 0.06 75.81 ± 16.36
0.125 82.29 ± 16.32∗ 0.19 ± 0.07 65.18 ± 10.69∗
0.500 82.85 ± 18.88∗ 0.24 ± 0.07∗ 74.12 ± 14.79
1.000 82.58 ± 13.73∗ 0.21 ± 0.05∗ 64.62 ± 14.45∗
Ileum
0.000 38.96 ± 8.70 0.19 ± 0.06 62.33 ± 14.08
0.125 35.51 ± 8.23∗ 0.22 ± 0.11∗ 60.68 ± 9.81
0.500 37.68 ± 7.39 0.21 ± 0.06 64.13 ± 15.83
1.000 37.07 ± 6.78 0.18 ± 0.03 70.19 ± 17.27∗
in one of eight mice administered 0.125mg/g of muricid
extract, andmild inflammation associated with crypt atrophy
was observed in the ileum of 2/7 mice receiving 0.5mg/g
extract (Figure 2(a)). Focal necrosis within the basal region
of villi was also evident in the ileum of one mouse receiving
0.125mg/g extract.This response was associated with chronic
inflammation of the lamina propria and widespread crypt
atrophy resulting in villous flattening and a decrease in villous
height (Figure 2(b)). Ileum cell height and density displayed
an inconsistent response (Table 2). No significant effects were
observed at the two higher doses of extracts. However inmice
administered 0.125mg/g extract, mean villous height was
significantly less (𝑃 = 0.038) and cell density was significantly
greater (𝑃 = 0.006) than in control animals (Table 2).
Ileum crypt depth was significantly less than controls in mice
administered 1.0mg/g (𝑃 < 0.001).
Overall, mucosal atrophy and inflammation were absent
from the small intestines of all control mice and mice
administered the highest dose of 1.0mg/g muricid extract.
No hemorrhage or ulcers were observed, but a low incidence
of inflammation and atrophy was detected in the duodenum
and ileum of one to two mice administered lower doses of
the extract. The lack of dose dependence suggests that these
extract-induced gastrointestinal effects are idiosyncratic.
Many anticancer drugs are known to induce mucosal inflam-
mation, atrophy andnecrosis [26]. For example,methotrexate
is associated with crypt and villous atrophy as a consequence
of apoptosis and S-phase cell cycle inhibition [42, 43]. Bromi-
nated isatins, including 6-bromoisatin, induce apoptosis and
inhibit cell proliferation in a variety of cancer cell lines [2, 28].
A semipurifiedmuricid extract has also been shown to reduce
non-transformed intestinal epithelial cell (IEC-6) viability by
>80% in vitro [1]. However, this in vivo study indicates a
significant increase in enterocyte density in the duodenum at
the two higher extract doses, and in the ileum at 0.5mg/mL.
A concurrent increase in villous height and cell density is
usually indicative of mucosal hyperplasia [26]. Hyperplasia
can arise through compensatory cell proliferation, which
occurs as a regenerative response to villous atrophy [26].
Althoughmucosal atrophy was generally localised, it is possi-
ble that significant increases in cell density and villous height
reflect regenerative proliferation. Intestinal metabolism of 6-
bromoisatin may promote intestinal hyperplasia, as isatin is
known to induce hypermetabolism in neuroblastoma cells
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Table 3: Mean (±S.D.) morphometric values for colon toxicity indicators in control mice (0.000mg/g extract,𝑁 = 4) and mice administered
0.125mg/g (𝑁 = 8), 0.5mg/g (𝑁 = 7), and 1.0mg/g (𝑁 = 6) of muricid extract (ME).






0.000 13.66 ± 1.90 0.18 ± 0.05
0.125 13.78 ± 2.31 0.17 ± 0.05
0.500 14.00 ± 2.64 0.19 ± 0.06
1.000 13.50 ± 2.71 0.18 ± 0.05
Distal
0.000 22.77 ± 3.34 0.21 ± 0.07
0.125 23.23 ± 3.53 0.19 ± 0.05
0.500 22.43 ± 3.81 0.18 ± 0.04
1.000 23.05 ± 4.01 0.19 ± 0.04
(a)
(b)
Figure 3: Transverse sections of colon abscesses stained with hae-
matoxylin. (a) Proximal colon abscess in a control mouse (0.0mg/g
muricid extract) characterised by chronic inflammation and crypt
atrophy, and (b) a distal colon abscess with mild inflammation and
localised crypt atrophy in a mouse administered 1.0mg/g muricid
extract. Abbreviations: C, crypt; IF, inflammatory infiltrate; LU,
lumen; MS, muscularis. Scale bars = 100 𝜇m.
[44]. Furthermore, isatin is reduced to the uraemic metabo-
lite dioxindole byNADPH-P450 reductase (NPR) [33], which
is highly expressed in enterocytes [45]. However, reduction
of 6-bromoisatin to isatin in the intestine is unlikely as GST-
mediated debromination is typically a phase II postoxidative
reaction [31].Thus, 6-bromoisatin is likely to avoid significant
metabolism until entry to the liver.
Transcellular absorption coupled with a limited capac-
ity for indole metabolism in the intestinal mucosa also
provides a mechanistic foundation for enterocyte toxicity
induced by tyrindoleninone. Of the enzymes required for
xenobiotic debromination and endogenous indole metabo-
lism, glutathione-S-transferase (GST) [46], and most likely
CYP2C19 occur in the intestinal mucosa [47]. However,
tyrindoleninone oxidation is likely to be negligible or vari-
able, as CYP2C19 only plays a minor role in indole oxida-
tion [33] and is polymorphically expressed [48]. As GST-
mediated debromination is a phase II process that occurs
after oxidation by CYP2E1 [31], debromination capacity may
also be limited. Consequently, brominated indoles within the
muricid extract are predicted to undergo minimal intesti-
nal metabolism. Previous studies have demonstrated the
enhancement of the AARGC in the distal colon by the muri-
cid extract [6], which provides further evidence for limited
metabolism of the bioactive brominated indoles within the
small intestine.
3.4. Gastrointestinal Effects: Colon. In contrast to the small
intestine, there were no histological signs of toxicity within
the proximal or distal colon, such as hemorrhage, atrophy,
or changes in crypt height. No evidence of haemorrhage
or ulcers was revealed after examination of all 75 proximal
and 75 distal colon sections in any of the control mice or
mice administered muricid extract. No significant differ-
ences in proximal colon crypt height (𝑃 = 0.577) or cell
density (𝑃 = 0.086) were detected between control mice
and those receiving muricid extract (Table 3). Similarly, no
significant differences in distal colon crypt height (𝑃 =
0.442) or cell density (𝑃 = 0.960) were detected between
control mice and those receiving muricid extract (Table 3).
Abscesses consisting of mild to chronic inflammation and
crypt atrophy were observed in the proximal colon of one
control mouse (Figure 3(a)), as well as distal colon of two
control mice. Abscesses were also detected in the proximal
colon of one mouse each in the 0.125 and 1.0mg/g extract
treatment groups, in three mice administered 0.5mg/g of
muricid extract, and onemild case in the distal colon for each
of the 0.125mg/g and 1.0mg/g treatment mice (Figure 3(b)).




Figure 4: Transverse liver sections showing (a) focal necrosis (arrow head), (b) submassive necrosis (arrow head), and (c) macro- and
microvesicular change (arrow head) in mice administered 0.125mg/g muricid extract stained in haematoxylin and eosin, (d) unstained
macrovesicular inclusions (arrow heads) and (e) microvesicular fatty inclusions stained with Oil Red O (arrow heads) in mice administered
0.125mg/g muricid extract, and (f) normal hepatocytes in a control mouse stained with haematoxylin and eosin. Abbreviations: A, artery;
BD, bile duct; CV, central vein (centrilobular, zone 3); N, nucleus; PV, portal vein (periportal, zone 1). Scale bars = 100 𝜇m (a-b) and 10 𝜇m
(c)–(f).
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Two out of seven mice treated with 0.5mg/g muricid extract
presented chronic inflammation in the distal colon. Although
abscesses and inflammation were present in the colon of a
small proportion of mice, their presence in both control and
treated animals suggests that these abscesses were unlikely to
be a toxic response to the muricid extract.
The observed lack of toxicity of the muricid extract in the
colon is a positive sign for potential use in the prevention
or treatment of colon cancer. Although the potential for
idiosyncratic toxicity in the small intestine is of concern,
mice in our previous in vivo study progressively increased in
weight with no significant difference in final weight between
treatment and control groups after 4 weeks of daily extract
administration [6]. This suggests that any idiosyncratic effect
has a negligible impact on intestinal absorption and nutri-
tional status. Direct consumption of the muricid molluscs,
or administration of the bioactive muricid extract with food,
may provide a means of reducing the potential idiosyncratic
gastrotoxicity, as food increases circulation and intestinal
metabolism thereby decreases drug residence time [41].
3.5. Hepatotoxicity. Due to the reduced diversity and con-
centration of P450 enzymes in intestinal microsomes [49],
intestinal metabolism of 6-bromoisatin and tyrindoleninone
is predicted to be minimal. However upon entry to the liver,
detoxification and conjugation in preparation for urinary
excretion are expected to progress in a similar manner to that
described for indole and isatin metabolites generated during
tryptophan metabolism [29, 33]. The liver is the principle
organ of biotransformation and contains cytochrome P450
and conjugation enzymes [26]. Consequently, hepatotoxicity
is a major cause of preclinical, clinical, and approved drug
withdrawal [27]. In this study, evidence for hepatotoxicitywas
detected in less than 40%of allmice administered themuricid
extract and together with a lack of dose dependence suggests
hepatic injury is idiosyncratic.
No evidence for the presence of Mallory bodies, por-
phyrin, haemosiderin, lipofuscin, or accumulated bile was
found after examination of all 75 triplicate liver sections from
control mice and mice administered muricid extract. How-
ever, focal haemorrhage was evident in one of four control
animals and one of eight mice administered 0.125mg/gmuri-
cid extract. Three mice at each of the higher doses (0.5mg/g,
𝑛 = 7; 1.0mg/g, 𝑛 = 6) presented focal haemorrhage in the
liver. Necrosis was observed in 2/8 and 1/6mice administered
0.125mg/g and at 1.0mg/g extract, respectively. Focal cen-
trilobular (zone 3) necrosis was present in mice administered
1.0mg/g and 0.125mg/g extract (Figure 4(a)). Necrosis within
another mouse administered 0.125mg/g extract was sub-
massive in nature, with a centrilobular distribution extend-
ing to adjacent periportal (zone 1) regions (Figure 4(b)).
Macrovesicular and microvesicular cytoplasmic changes
(Figure 4(c)) were observed within hepatocytes proximal to
Glisson’s capsule in some of the mice administered the lower
doses of muricid extract. Macrovesicular changes occurred
in half the mice administered 0.125mg/g (𝑛 = 8) and 2/7
mice administered 0.5mg/g muricid extract. Although these
inclusions failed to stain postfixation with osmium tetroxide









































Inflammation severity (grade) and distribution (zone)
Figure 5: Comparison of the severity and distribution of hepatic
inflammatory infiltrates in control mice (black bars, 𝑁 = 4) and
mice administered 0.125mg/g (dark grey filled bars, 𝑁 = 8),
0.5mg/g (light grey filled bars,𝑁 = 7), and 1.0mg/g (white bars,𝑁 =
6) muricid extract on a daily basis. Values are the mean frequency of
foci/20 fields of view at 200x magnification. Inflammation severity
is graded as follows grade 1 (>5 ≤10); grade 2 (>10 ≤20); grade 3
(>20 ≤30), grade 4 (>30) lymphocytes/foci. The distribution of foci
is categorised by acinous zone: zone 1, periportal (portal triad); zone
2, periportal centrilobular; zone 3, centrilobular (central vein).
Oil Red O for neutral lipids was observed on occasion
(Figure 4(e)). Microvesicular changes stained consistently
with Oil Red O (Figure 4(e)) and were evident in three
and two mice administered 0.125mg/g and 0.5mg/g muricid
extract, respectively.
Macrovesicular change coincided with microvesicular
change in all cases. Necrosis and fatty change were not
observed in control animals (Figure 4(f)) or any of the mice
administered the high dose of 1.0mg/g extract. Mean fre-
quency of inflammatory foci was significantly greater in
mice administered muricid extract relative to the controls
(Table 4, 𝑃 < 0.001). Similarly, the mean frequency of grade
1, 2, and 3 foci increased in all doses of muricid extract,
relative to the controls (Figure 5). Grade 4 inflammatory
foci were only observed in treatment groups and were of
greatest frequency in animals administered 1.0mg/g extract
(Figure 5). Despite these trends, only the frequency of grade
1 foci was significantly greater in mice administered extract
than in control animals (𝑃 = 0.001). The frequency of zone 3
(centrilobular) inflammatory foci also significantly increased
in mice administered muricid extract compared to control
animals (𝑃 = 0.001).The frequency of zone 1 (periportal) and
zone 2 (midzonal) inflammatory foci displayed no significant
differences with extract administration relative to controls
(Figure 5).
Hepatocyte density displayed an inconsistent dose
response in mice treated with muricid extract (Table 4).
Hepatocyte density peaked in mice administered the lowest
extract dose of 0.125mg/g and was significantly greater than
in control mice at this dose and at 0.5mg/g (𝑃 ≤ 0.001). In
contrast, hepatocyte density was similar to controls in mice
administered the higher dose of 1mg/g extract. Hepatocyte
diameter was the lowest in mice treated with 0.125mg/g
extract (Table 4), with a significantly larger hepatocytes
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Table 4: Frequency and mean morphometric values (±S.D.) for hepatotoxicity indicators in control mice (0.0mg/g, 𝑁 = 4) and mice
administered 0.125mg/g (𝑁 = 8), 0.5mg/g (𝑁 = 7), and 1.0mg/g (𝑁 = 6) of muricid extract (ME). Significant differences between control











0.000 23.73 ± 4.31 18.98 ± 3.20 4.47 ± 1.07 0.15 ± 0.42
0.125 30.16 ± 5.51∗ 15.16 ± 2.43∗ 5.93 ± 2.09∗ 0.55 ± 0.90∗
0.500 27.68 ± 5.95∗ 16.46 ± 2.65∗ 5.91 ± 1.57∗ 0.73 ± 1.11∗
1.000 24.80 ± 4.98 17.29 ± 2.88∗ 5.43 ± 1.36∗ 0.76 ± 0.07∗
in control mice in comparison to all mice treated with
muricid extract (𝑃 < 0.001 for all doses). Sinusoid diameter
was significantly greater in mice administered the extract
(𝑃 < 0.001) than in control animals.
Microvesicular and macrovesicular steatosis, necrosis
and inflammation are hallmarks of nonalcoholic steatohep-
atitis (NASH) [50]. Steatosis, as confirmed by Oil Red O, was
observed in a few mice administered the two lower doses
of muricid extract but was not observed at all in the high-
dose treatment group. Necrosis was only observed in two
mice at the lowest dose whereas focal hemorrhages were
more frequent at the two higher doses. Inflammation and a
significant increase in the frequency of centrilobular inflam-
matory foci were also evident in some mice administered
the extract. As these lesions were absent from control mice,
it appears that daily administration of muricid extract does
have the potential to induce idiosyncratic hepatic injury.
Absence of accumulated bile, Mallory bodies, porphyrin
and haemosiderin suggests that bile duct obstruction is not
responsible for muricid extract-induced hepatotoxicity.
Indoxyl sulphate is predicted to be a significant product
of muricid extract metabolism and could be responsible for
some of the observed hepatotoxicity. Indoxyl sulphate is an
endogenous conjugation product of tryptophan metabolism
and is excreted in the urine [29]. Accumulation of indoxyl
sulphate is known to stimulate production of reactive oxygen
species (ROS) [35], which is strongly implicated in the
development of nonalcoholic fatty liver disease (NAFLD)
and progression to NASH, cirrhosis and cancer [51, 52].
Tyrindoxyl sulphate is a minor constituent of the muricid
extract and is predicted to undergo paracellular absorption
and hepatic debromination to indoxyl sulphate by CYP2A6,
CYP2E1 [30] or GST [31]. Debromination, oxidation [53] and
conjugation [29] of other muricid indoles (>25% of extract)
may also yield indoxyl sulphate. Accumulation of indoxyl
sulphate may be further enhanced by its binding affinity to
serum albumin and the influence of indomethacin, a nons-
teroidal antiinflammatory indole which inhibits renal uptake
[34]. Methanethiol generation during hepatic metabolism
of tyrindoleninone, tyrindolinone, or tyriverdin may also
contribute to steatosis.Metabolism ofmethionine yields toxic
methanethiol, which inhibits enzymes that provide protec-
tion from peroxidative damage [54]. As excessive dietary
intake increases lipid peroxidation in the liver [55], it is
possible that methanethiol derived from the muricid extract
contributes to lipid accumulation in some mice. Although
muricid extract may result hepatic injury synonymous with
NASH, observations of hepatocyte hyperplasia in mice
administered the extract suggest a regenerative response to
hepatic injury [26].
In addition to hepatic injury, indoxyl sulphate accumula-
tion may also result in renal injury, Indoxyl sulphate induces
glomerular hypertrophy, stimulates cell proliferation [35] and
inhibits active tubular secretion [56]. This is partially sup-
ported by the significant increase in kidney weight observed
inmice administered 1.0mg/g of themuricid extract (Table 1).
The potential for hepatic injury and impaired renal function
is of concern to the development of crude muricid extract
as an oral chemopreventative. Quantification of indoxyl
sulphate after extract administration is required to deter-
mine the potential for accumulation to toxic levels. Further
hydrolysis and purification of the muricid extract to reduce
the amount of tyrindoxyl sulfate and indoles in favor of
6-bromoisatin may help reduce the potential for liver and
kidney damage.
Interindividual variability and a lack of consistent dose-
dependent responses to the muricid extract imply idiosyn-
crasy. Idiosyncratic hepatotoxicity typically occurs as a result
of individual immunologic or metabolic susceptibility [57].
As all mice administered the muricid extract appeared
consistent in health, with no signs of rash or fever that would
imply an immune reaction, idiosyncratic hepatotoxicity is
likely to be of metabolic origin. The P450 isoforms CYP2E1
[53] and CYP2C19 [48] exhibit significant interindividual
variation and are known to be involved in endogenous
indole metabolism and xenobiotic debromination. As indole
oxidation is catalysed by CYP2E1 [53], and to a lesser extent
CYP2C19 [33], variability in the expression of these isoforms
may alter the kinetics of metabolite detoxification. Fur-
thermore, nutritional status of individual mice could influ-
ence metabolite absorption, bioavailability, and metabolism.
Gastric emptying into the intestinal lumen stimulates the
production of bile acids and pancreatic enzymes, which
can act as wetting agents, enhance fat solubility, and alter
cell membrane functions [41]. Intestinal circulation is also
increased in a fed state, which increases the rate of drug
metabolism and decreases intestinal residence time [41].
As mice were fed ad libitum, intestinal metabolism of the
bioactive compounds and hence the incidence and severity
of extract-induced gastrointestinal effects will depend on
the timing of individual food intake, in relation to extract
administration.
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4. Conclusions
Thefindings of this investigation indicate that daily consump-
tion of muricid extract has no major visible signs of toxicity
but can havemild gastrointestinal effects and induce idiosyn-
cratic hepatotoxicity in somemice.The lack of co-occurrence
in individuals suggests that observations of gastrointestinal
toxicity and hepatotoxicity are unrelated. Gastrointestinal
effects were characterised by heavier small intestines and
villous hyperplasia in the duodenum. Extract-induced hepa-
totoxicity was primarily characterised by idiosyncratic injury
including, steatosis, necrosis, and inflammation. As drug-
induced hepatotoxicity is a major cause of preclinical drug
withdrawal [27], research into potential protective agents and
the origin of idiosyncratic expression is paramount to the
development ofmuricid extract as a CRC chemopreventative.
It is worth noting that muricid molluscs are regularly con-
sumed inmany countries, with noprevious reports of toxicity.
Consequently, the observed toxic effects may be less likely to
occur when the bioactive constituents are ingested in lower
concentrations in association with muricid meat. Therefore,
future development of the Muricidae as a medicinal food
for cancer prevention will require further research on the
purified active constituents and alternative delivery regimes,
such as incorporation of the extract into a controlled diet
rather than oral gavage.
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